CNS Activity
Sources: http://www.openaccessjournals.com/articles/lixisenatide-clinical-profile-and-available-evidence.pdf
Curator's Comment:: Known to be CNS penetrant in rodents. Human data not available.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P43220 Gene ID: 2740.0 Gene Symbol: GLP1R Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ADLYXIN Approved UseADLYXIN is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date1.46949118E12 |
Sample Use Guides
The starting dose of ADLYXIN is 10 mcg subcutaneously once daily for 14 days. Increase the dose to the maintenance dose of 20 mcg once daily starting on Day 15.
Route of Administration:
Other
In Vitro Use Guide
Curator's Comment:: In vitro, lixisenatide bound to human glucagon-like peptide-1 receptor (GLP-1R) with a greater affinity than native human GLP-1 (7-36 amide). In various in vitro and in vivo models of T2DM, lixisenatide improved glycemic measures and demonstrated promising pancreatic beta-cell-preserving actions.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA10BX10
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
||
|
WHO-ATC |
A10BX10
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
||
|
WHO-ATC |
A10AE54
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
||
|
WHO-ATC |
A10BJ03
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
||
|
NDF-RT |
N0000178480
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
320367-13-3
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
CHEMBL2108336
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
1440051
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | RxNorm | ||
|
C166988
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
LYXUMIA
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | APPROVED JUNE 2013 | ||
|
7387
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
Lixisenatide
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
SUB32251
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
74O62BB01U
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
M6875
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | Merck Index | ||
|
Lixisenatide
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
DB09265
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
4815
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY | |||
|
8970
Created by
admin on Sat Jun 26 18:19:02 UTC 2021 , Edited by admin on Sat Jun 26 18:19:02 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
